K-numberK242822
Device nameART-Plan+ (v.3.0.0)
ApplicantTherapanacea Sas
Product codeMUJ
Device classClass II
Decision dateFeb 25, 2025
DecisionSubstantially Equivalent
Regulation892.5050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

ART-Plan+ is a software platform for cancer radiotherapy planning that automatically contours organs at risk, lymph nodes, and tumors on CT and MR images using deep learning algorithms. It also generates automatic radiotherapy treatment plans for prostate cancer that users import into their own Treatment Planning System for dose calculation, review, and approval. The device is intended for use by trained medical professionals in hospitals and clinics treating patients 18 years and older.

Technological characteristics

Both ART-Plan+ and the predicate (Radiation Planning Assistant) use AI-based delineation methods for automatic contouring of regions of interest. ART-Plan+ offers deep-learning segmentation across multiple anatomical sites (head/neck, thorax, abdomen, pelvis, brain) on both CT and MR images, while the predicate provides autocontouring for a range of structures. Both devices allow creation of contours and treatment plans that users import into their own Treatment Planning System for dose calculation and approval.

Test standards cited

Not stated in this summary.

Substantial equivalence argument

ART-Plan+ is substantially equivalent because it performs the same intended functions as the predicate using the same AI-based approach: both enable external beam radiotherapy planning with photon beams using CT images, both automatically contour regions of interest, and both allow users to export plans for independent dose calculation. The device was validated through non-regression testing (DSC ≥0.8 for new organs, no more than -5% regression for existing structures), qualitative expert review (≥85% acceptable), inter-expert variability comparison (≥Mean DSC inter-expert with -5% tolerance), and clinical plan acceptability (≥93% of automatic plans clinically acceptable). All validation datasets were representative of worldwide radiotherapy populations, and all acceptance criteria were met, demonstrating that ART-Plan+ performs equivalently to the predicate with no additional claims or risks.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →